Safety recommendation
It is recommended that PrescQIPP CIC supports its subscribers to identify the potential risk of prescribing propranolol to patients in at-risk groups.
Response:
PrescQIPP CIC have shared the HSIB safety report through various platforms which include virtual meetings, newsletters and on Twitter. It has also produced a bulletin, an audit and searches for GP clinical systems to support GPs in identifying patients at risk so they can have their medicines reviewed and be given advice where appropriate.
To help inform patients of the risks of propranolol, PrescQIPP CIC have also produced some patient information materials highlighting the risks of propranolol and signposting to healthcare professionals for further advice. PrescQIPP CIC subscribers can access these resources via its website to support review of current practice and implement change. The following actions have also been taken:
- The HSIB report was sent to PrescQIPP subscriber leads via e-mail in February 2020.
- The HSIB report was mentioned in a subscriber leads meeting in February 2020. The PrescQIPP hot topic resource on this subject was produced in February and is available to subscribers. This resource includes a bulletin discussing the recommendations and potential actions, clinical system searches to identify at risk patients, an audit and patient information resources warning of the safety risks with propranolol.
- Resources have been publicised on Twitter in March 2020 with @hsib_org copied into tweet.
- PrescQIPP resources were promoted on the senior leads call in March 2020.
Response received on 13 July 2020.